Toralgen develops a poly-bile nanoparticle platform designed to enable oral delivery of biologics in a single, simple-to-fabricate “nanopill.” The platform aims to eliminate common challenges of oral drug delivery while localizing agents to potentially improve efficacy and safety. Toralgen currently has two candidates in preclinical testing for oral delivery of diabetes agents and is also studying treatments for autoimmune disorders. The company was accepted into the FDA’s Emerging Technology Program, enabling more regular dialogue with the agency as it advances the platform. Toralgen will use the proceeds from its recent financing to further development of the nanoparticle platform and to advance industry partnerships. The company emphasizes strong preclinical data and a growing team as drivers of its near-term plans.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2024